Indication

Vitiligo

Vitiligo is a chronic, acquired autoimmune disorder of the integumentary system characterized by the selective, progressive destruction of melanocytes. Read more about Vitiligo

0 drugs 0 manufacturers

Advertisement

Drugs that treat it

Common Vitiligo therapies.

0 drugs

No drugs are available

This indication does not currently contain public drugs.

Filter & compare in the drug finder →Opens the drug finder with Vitiligo preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Vitiligo.

Vitiligo is a chronic, acquired autoimmune disorder of the integumentary system characterized by the selective, progressive destruction of melanocytes.

It can develop at any age across all skin phototypes and populations, though onset frequently occurs before the age of thirty.

Pathophysiologically driven by an aberrant autoreactive immune attack against pigment-producing cells, the condition clinically manifests as well-demarcated, amelanotic white macules and patches on the skin, mucosal membranes, and hair follicles.

Lesions often demonstrate a predilection for the face, acral extremities, and intertriginous areas, presenting as localized, segmental, or widespread nonsegmental patterns.

Personalize your experience

Follow Vitiligo and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it